• 1. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropylamines

Professional Introduction to 3-(4-Bromophenyl)-N,N-diethylpropan-1-amine (CAS No. 804431-56-9)

3-(4-Bromophenyl)-N,N-diethylpropan-1-amine is a significant compound in the field of pharmaceutical chemistry, characterized by its unique structural and functional properties. This compound, identified by the CAS number 804431-56-9, has garnered attention due to its potential applications in drug discovery and molecular research. Its molecular structure, featuring a brominated phenyl ring and diethylamino substituents, makes it a versatile intermediate in synthesizing various bioactive molecules.

The chemical formula of 3-(4-Bromophenyl)-N,N-diethylpropan-1-amine can be represented as C₁₄H₂₀NBr. This molecular composition contributes to its reactivity and utility in organic synthesis. The presence of the bromine atom at the para position of the phenyl ring enhances its participation in various chemical reactions, such as cross-coupling reactions, which are pivotal in constructing complex molecular architectures.

In recent years, there has been a surge in research focusing on developing novel pharmacophores with improved efficacy and reduced side effects. 3-(4-Bromophenyl)-N,N-diethylpropan-1-amine has emerged as a valuable building block in this context. Its structural features allow for modifications that can fine-tune its pharmacological properties, making it a candidate for designing new therapeutic agents. For instance, studies have explored its role in developing compounds that target neurological disorders, where its ability to interact with specific biological receptors is highly beneficial.

The synthesis of 3-(4-Bromophenyl)-N,N-diethylpropan-1-amine typically involves multi-step organic reactions, starting from readily available precursors. The bromination step is crucial and often employs reagents like N-bromosuccinimide (NBS) under controlled conditions to ensure high yield and purity. The subsequent formation of the diethylamino group is achieved through nucleophilic substitution or reductive amination techniques. These synthetic pathways highlight the compound's importance as a synthetic intermediate in industrial and academic settings.

One of the most compelling aspects of 3-(4-Bromophenyl)-N,N-diethylpropan-1-amine is its potential in medicinal chemistry. Researchers have leveraged its scaffold to develop molecules with anti-inflammatory, analgesic, and even anticancer properties. The bromine atom's electronic effects modulate the compound's interactions with biological targets, enhancing binding affinity and selectivity. This has led to several preclinical studies investigating derivatives of this compound for their therapeutic potential.

The pharmacokinetic profile of compounds derived from 3-(4-Bromophenyl)-N,N-diethylpropan-1-amine is another area of active investigation. Understanding how these molecules are absorbed, distributed, metabolized, and excreted (ADME) is crucial for optimizing their clinical efficacy. Advanced computational methods, such as molecular docking and pharmacokinetic modeling, have been employed to predict the behavior of these derivatives in vivo. These studies provide valuable insights into improving drug design strategies.

The role of computational chemistry in studying 3-(4-Bromophenyl)-N,N-diethylpropan-1-amine cannot be overstated. High-throughput virtual screening (HTVS) has enabled researchers to rapidly evaluate thousands of compounds for their binding affinity to target proteins. This approach has accelerated the discovery process by identifying promising candidates for further experimental validation. Moreover, quantum mechanical calculations have been used to elucidate the electronic structure and reactivity of this compound, providing a deeper understanding of its chemical behavior.

In conclusion, 3-(4-Bromophenyl)-N,N-diethylpropan-1-amine (CAS No. 804431-56-9) represents a fascinating compound with significant implications in pharmaceutical research. Its unique structural features make it a valuable tool for synthesizing novel bioactive molecules with potential therapeutic applications. As research continues to evolve, the utility of this compound is expected to expand further, driving advancements in drug discovery and molecular medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)